Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
27 hedge funds and large institutions have $225M invested in Sinovac Biotech, Ltd in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, reducing their positions, and 2 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
4% less funds holding
Funds holding: 28 → 27 (-1)
40% less capital invested
Capital invested by funds: $375M → $225M (-$150M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.18K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$162 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$58 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $184M | – | – | – |
|
|
VC
2
Vivo Capital
Palo Alto,
California
| $38.2M | – | – | – |
|
|
NAH
3
Neumann Advisory (HK)
Central,
Hong Kong
| $2.04M | – | – | – |
|
|
4
Wells Fargo
San Francisco,
California
| $109K | +$162 | +25 | +0.1% |
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $106K | – | – | – |
|
|
6
Morgan Stanley
New York
| $59.2K | +$5.18K | +800 | +10% |
|
|
7
UBS Group
Zurich,
Switzerland
| $14.4K | +$58 | +9 | +0.4% |
|
|
HI
8
Horizon Investments
Charlotte,
North Carolina
| $336 | – | – | – |
|
SVA Hedge Fund Activity: Q3 2025 in Review
27 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2025, worth a combined $225M — down 40% from $375M a quarter earlier.
Fund positioning in SVA was balanced in Q3 2025: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.18K.
- 27 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2025, down from 28 in Q2 2025.
- Funds reported $225M of Sinovac Biotech, Ltd stock for Q3 2025, down 40% quarter-over-quarter.
- 2 funds opened new Sinovac Biotech, Ltd positions in Q3 2025 and 2 closed out, a net change of 0 holders.
- The largest Sinovac Biotech, Ltd buyer in Q3 2025 was Morgan Stanley, an estimated $5.18K added.
Based on aggregated 13F filings for Q3 2025.